Adjuvant treatment of postmenopausal women w/ hormone receptor positive invasive early breast cancer. Extended adjuvant treatment of invasive early breast cancer in postmenopausal women who have received 5 yr of standard adjuvant tamoxifen therapy. 1st-line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer; advanced breast cancer after relapse or disease progression in women w/ natural or artificially induced postmenopausal endocrine status who have previously been treated w/ antiestrogens.
Not indicated in hormone receptor negative diseases. Monitor overall bone health during treatment. Measure LH, FSH &/or estradiol levels before initiating treatment in patients w/ unclear menopausal status. Co-administration w/ tamoxifen, other antiestrogens or estrogen-containing therapies. May affect ability to drive & use machines. Renal (CrCl <10 mL/min) & severe hepatic impairment (Child-Pugh score C). Premenopausal women. Not recommended in childn & adolescents up to 17 yr.
Sign Out
